ArticleFrontiers in oncology2023

Cost-effectiveness evaluation based on two models of first-line atezolizumab monotherapy and chemotherapy for advanced non-small cell lung cancer with high-PDL1 expression.

Chuan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.